- Home
- KIO vs BBNX Comparison
KIO vs BBNX Comparison
Compare KIO & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KIO | BBNX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.1M | 493.1M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | KIO | BBNX |
|---|---|---|
| Price | $11.19 | $14.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | 142.1K | ★ 944.9K |
| Earning Date | 01-01-0001 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.65 | $8.80 |
| 52 Week High | $12.83 | $32.71 |
Technical Indicators
Market Signals| Indicator | KIO | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 65.24 |
| Support Level | $11.11 | $9.34 |
| Resistance Level | $11.25 | $15.26 |
| Average True Range (ATR) | 0.08 | 1.04 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 24.07 | 90.65 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.